Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
• High-risk Myelodysplastic Syndromes
• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Adaptive Dual-Target CAR-T Cells

Snippet

Sponsor: Beijing Biotech | Conditions: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1, Phase 2 | Status: RECRUITING